As for anti-PD-1 blockade, the IFN-γ gene signature (IDO1, CXCL10, CXCL9, HLA-DRA, STAT1, and IFNG) predicts the response to anti-PD-1 therapy in multiple tumors, including melanoma [18]. This evidence concerns the gene IDO1 and melanoma.